Can-Fite Granted US Patent on CF101 for Rheumatoid Arthritis (RA).The patent confers exclusive right to CF101 in the treatment of RA until 2023 Dr. Ilan Cohn, Deputy CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Can-Fite, said today that "this current patent and the previously issued patent on CF101 for the treatment of cancer are substantial additions to the patent portfolio of Can-Fite because these patents afford a significant extension of the Company's exclusive right to the drugs it develops. Can-Fite estimates that these patents, combined with previously issued and future patents, will set an extremely high barrier to entry for any potential competitors and will secure Can-Fite's dominant position in its field." PETACH TIKVA, Israel -- Can-Fite BioPharma (TASE TASE Tel Aviv Stock Exchange TASE The All Seeing Eye TASE Tactical Air Support Element TASE Thrust Assessment Support Environment TASE Telecontrol Application Service Elements (IEC communications protocol) :CFBI CFBI California Family Business Institute, LLC CFBI Center for Functional Brain Imaging ), a biotechnology company traded on the Tel Aviv Stock Exchange Tel Aviv Stock Exchange Israel's only stock exchange. , has been granted an exclusive patent by the US Patent and Trademark Office (USPTO USPTO abbr. United States Patent and Trademark Office ) on CF101 for the treatment of RA, valid until 2023. This patent, which sets a significant barrier to entry for competition in the field of RA, constitutes a substantial addition to Can-Fite's patent portfolio and promotes the Company's ability to secure long term exclusive rights to the RA drugs it develops. It is important to note that the US market represents an estimated 40% of the global pharmaceutical market, and securing long term exclusive rights in this major pharmaceutical market is of utmost importance. Can-Fite was also granted another patent, which secures exclusive rights to drugs that target the A3 adenosine receptor The adenosine receptors are a class of G-protein coupled receptors with adenosine as endogenous ligand. A1 adenosine receptor The adenosine A1 receptor has been found to be ubiquitous throughout the entire body. , including the CF101 and CF102 drugs which are being developed for the treatment of cancer. Dr. Ilan Cohn, Deputy CEO of Can-Fite, said today that "this current patent and the previously issued patent on CF101 for the treatment of cancer are substantial additions to the patent portfolio of Can-Fite because these patents enable a significant extension of the Company's exclusive right to the drugs it develops. Can-Fite estimates that these patents, and the previously issued and future ones, will set an extremely high barrier to entry for any potential competitors and will secure Can-Fite's dominant position in its field." Can-Fite develops targeted drugs that specifically attacks affected cells without compromising normal body systems, and therefore have a favourable safety profile. The company's drugs are based on a scientific concept suggesting A3 Adenosine receptor (A3AR), the drug target is expressed on the surface of affected cells. The A3AR was found during the Phase IIa study to serve as a biological marker to predict patient response to the drug. It is analyzed in a simple blood test assay. Can-Fite is developing its first drug, CF101, for 3 clinical indications in the field of inflammatory diseases, including: RA (ongoing phase IIb clinical trials in the US), Dry Eye Syndrome dry eye syndrome Conjunctivitis arida, keratitis sicca, keratoconjunctivitis sicca, xerophthalmia Medtalk Dryness of eyes, often due to ↓ tear secretion Clinical Dry, greasy, thickened and focally denuded cornea, which may progress to keratomalacia, corneal and Psoriasis (Phase II trials scheduled to begin in Israel). The company has also commenced the development of CF102 in the treatment of liver cancer Liver Cancer Definition Liver cancer is a relatively rare form of cancer but has a high mortality rate. Liver cancers can be classified into two types. . Can-Fite recently announced that it had entered into an exclusive license agreement with the Japanese Seikagaku Corporation to develop and market CF101 in Japan for the treatment of inflammatory diseases, including RA but excluding ophthalmology ophthalmology (ŏf'thălmŏl`əjē), branch of medicine specializing in the anatomy, function and diseases of the eye. Ophthalmologists specialize in the medical and surgical treatment of eye disorders, vision measurements for indications. Under the terms of this agreement, Can-Fite is to receive an aggregate sum of up to US$ 19.5 million, contingent to achieving agreed milestones, and collect substantial royalties from the sales of CF101 in Japan and from the sales of raw materials needed for manufacturing. In the third quarter of 2006, the Company reported initial income of about NIS Niš or Nish (both: nēsh), city (1991 pop. 175,391), SE Serbia, on the Nišava River. An important railway and industrial center, it has industries that manufacture textiles, electronics, spirits, and locomotives. 12.9 million from the first payment under the terms of this agreement. CAN-FITE BIOPHARMA LTD LTD 1 Laron-type dwarfism 2 Leukotriene D 3 Long-term depression, see there 4. Long-term disability is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by researcher Prof. Pnina Fishman and patent attorney Dr. Ilan Cohn. The Company focuses on the development of molecule-based drugs that inhibit the development of cancer or inflammatory cells. The market for the company's drugs is estimated at billions of dollars. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion